166 related articles for article (PubMed ID: 37517154)
1. Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy.
Nordenskjöld A; Fohlin H; Rosell J; Bengtsson NO; Fornander T; Hatschek T; Lindman H; Malmström P; Rydén L; Wallgren A; Stål O; Nordenskjöld B
Breast; 2023 Oct; 71():63-68. PubMed ID: 37517154
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen.
Rosell J; Nordenskjöld B; Bengtsson NO; Fornander T; Hatschek T; Lindman H; Malmström PO; Wallgren A; Stål O; Carstensen J
Acta Oncol; 2017 Apr; 56(4):614-617. PubMed ID: 28080180
[TBL] [Abstract][Full Text] [Related]
3. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
4. Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan.
Matsuyama Y; Tominaga T; Nomura Y; Koyama H; Kimura M; Sano M; Miura S; Takashima S; Mitsuyama S; Ueo H; Ohashi Y
Ann Oncol; 2000 Dec; 11(12):1537-43. PubMed ID: 11205460
[TBL] [Abstract][Full Text] [Related]
5. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.
Dignam JJ; Wieand K; Johnson KA; Fisher B; Xu L; Mamounas EP
J Natl Cancer Inst; 2003 Oct; 95(19):1467-76. PubMed ID: 14519753
[TBL] [Abstract][Full Text] [Related]
6. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
Fisher B; Dignam J; Bryant J; DeCillis A; Wickerham DL; Wolmark N; Costantino J; Redmond C; Fisher ER; Bowman DM; Deschênes L; Dimitrov NV; Margolese RG; Robidoux A; Shibata H; Terz J; Paterson AH; Feldman MI; Farrar W; Evans J; Lickley HL
J Natl Cancer Inst; 1996 Nov; 88(21):1529-42. PubMed ID: 8901851
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
8. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
Cuzick J; Forbes JF; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A;
J Natl Cancer Inst; 2007 Feb; 99(4):272-82. PubMed ID: 17312304
[TBL] [Abstract][Full Text] [Related]
10. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries.
Jones ME; van Leeuwen FE; Hoogendoorn WE; Mourits MJ; Hollema H; van Boven H; Press MF; Bernstein L; Swerdlow AJ
Breast Cancer Res; 2012 Jun; 14(3):R91. PubMed ID: 22691381
[TBL] [Abstract][Full Text] [Related]
11. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
Tormey DC; Gray R; Falkson HC
J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
[TBL] [Abstract][Full Text] [Related]
12. Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial.
Ekholm M; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Rydén L;
Eur J Cancer; 2019 Mar; 110():53-61. PubMed ID: 30769227
[TBL] [Abstract][Full Text] [Related]
13. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.
Fisher B; Costantino JP; Redmond CK; Fisher ER; Wickerham DL; Cronin WM
J Natl Cancer Inst; 1994 Apr; 86(7):527-37. PubMed ID: 8133536
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Fédération Nationale des Centres de Lutte Contre le Cancer Breast Group.
Delozier T; Spielmann M; Macé-Lesec'h J; Janvier M; Hill C; Asselain B; Julien JP; Weber B; Mauriac L; Petit JC; Kerbrat P; Malhaire JP; Vennin P; Leduc B; Namer M
J Clin Oncol; 2000 Oct; 18(20):3507-12. PubMed ID: 11032592
[TBL] [Abstract][Full Text] [Related]
15. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Cuzick J; Sestak I; Baum M; Buzdar A; Howell A; Dowsett M; Forbes JF;
Lancet Oncol; 2010 Dec; 11(12):1135-41. PubMed ID: 21087898
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen for early breast cancer.
Early Breast Cancer Trialists' Collaborative Group
Cochrane Database Syst Rev; 2001; (1):CD000486. PubMed ID: 11279694
[TBL] [Abstract][Full Text] [Related]
18. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
Buzdar AU;
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
[TBL] [Abstract][Full Text] [Related]
19. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
20. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Romero SA; Young K; Hickey M; Su HI
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD007245. PubMed ID: 33348436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]